Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

 
• By Jessica Merrill

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

Isometric double cube between white and black. Negotiation, diplomacy, cooperation, conflict and merging concept.
Merck & Co. is acquiring an autoimmune disease platform • Source: Shutterstock

More from Immunological

More from Therapy Areas